Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Other Non-Current Assets readings, the most recent being $3.4 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $3.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.4 million, a 0.0% change, with the full-year FY2025 number at $92000.0, down 2.13% from a year prior.
  • Other Non-Current Assets hit $3.4 million in Q4 2025 for Enanta Pharmaceuticals, up from $92000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.0 million in Q3 2022 to a low of $92000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $753000.0 (2022), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 4213.04% in 2022 and later tumbled 97.2% in 2025.
  • Enanta Pharmaceuticals' Other Non-Current Assets stood at $92000.0 in 2021, then surged by 4213.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then fell by 15.32% to $3.4 million in 2024, then changed by 0.0% to $3.4 million in 2025.
  • The last three reported values for Other Non-Current Assets were $3.4 million (Q4 2025), $92000.0 (Q3 2025), and $94000.0 (Q2 2025) per Business Quant data.